Project Grant SB1AI192001
Award Date 9/17/25
Completion Date 8/31/28
Dollars Obligated $969K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Windsor Mill, Milford Mill, MD 21244, USA
Similar Awards
- The federal Project Grant award of $299,697 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel broad-spectrum antifungal agent targeting cell wall biosynthesis. The goal is to create a mechanistically unique inhibitor of the enzyme 1-3-D-glucan synthase (GS) that demonstrates potent and wide-ranging fungicidal activity, including against echinocandin-resistant...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $306,872 to Cellia Science, Inc. to develop a rapid, point-of-care diagnostic tool for Spontaneous Bacterial Peritonitis (SBP), a severe complication of chronic liver disease. The project aims to integrate microfluidic-based sample preparation and advanced algorithm-driven cell classification to enable on-the-spot cell counting in ascitic...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The key objectives are to establish an effective formulation, conduct toxicological and stability studies, and prepare an Investigational New Drug (IND) application...
- This federal Project Grant award of $3,055,197.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of the project is to evaluate the potential impact of rapid detection of carbapenemase-producing organisms (CPOs) using a form-factor optimized phenotypic test paired with machine learning algorithms. The goal is to increase CPO detection, decrease time-to-identification of CPO...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
- This SBIR Phase I Project Grant award of $298,646, provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a rapid diagnostic test for identifying sepsis-causing pathogens from small blood volumes. The proposed DNA-based technology seeks to comprehensively detect and quantify a wide range of pathogens within a few hours, addressing limitations of current culture-based methods that require larger blood samples and...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,616 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Shy Therapeutics, LLC to develop a novel class of small molecule antifungal therapies. The project aims to identify and optimize new chemical compounds with potent activity against drug-resistant fungal strains such as Cryptococcus neoformans and Candida auris. Key objectives include using structure-activity relationship...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $999,316 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Pearl Diagnostics, Inc., a Baltimore-based small business. The grant supports the final integration and clinical testing required for FDA clearance of Pearl Diagnostics' lateral flow device (LFD) - a rapid, point-of-care urine test to diagnose invasive aspergillosis, an infection recently named a "critical" public...
- This $424,265 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on August 7, 2025 supports the development of an integrated "DIMS-RAMAN" platform to rapidly isolate and analyze bacterial cells from blood samples within 1-2 hours. The proposed system combines a novel density-shift immunocapture separation (DIMS) technique to directly separate microbial cells from whole blood, with Raman...